Welcome to issue 37 of Multiple Myeloma Research Review.
This issue begins with a retrospective, multinational report describing the clinical features associated with outcomes of patients with MM who had acquired SARS-COV-2 infection. There is also research demonstrating that autologous HSCT is an important therapy among patients with MM, even our elderly patients. Researchers from the US have performed some elaborate analyses of trial and real-world data to conduct indirect treatment comparisons between D-Rd (daratumumab, lenalidomide, dexamethasone; MAIA trial) and other standard-of-care regimens used for treating transplant-ineligible patients with newly diagnosed MM in community-based oncology practices in the US. The issue concludes with a health-related QOL analysis of the CASSIOPEIA randomised trial comparing VTd (bortezomib, thalidomide, dexamethasone) with versus without daratumumab in newly diagnosed, transplant-eligible MM.
We hope you enjoy the research selected, and we look forward to your comments and suggestions.
Dr Ken Romeril: email@example.com
Dr Henry Chan: firstname.lastname@example.org